Evofem Biosciences Announces Updated Date and Time for Fireside Chat at Cantor Global Virtual Healthcare Conference

Rhea-AI Summary

Evofem Biosciences, Inc. (NASDAQ: EVFM) announced a rescheduled virtual fireside chat at the 2020 Cantor Global Virtual Healthcare Conference, set for September 17, 2020, from 1:20 p.m. to 1:50 p.m. ET. Interested parties can access the live and archived webcast on Evofem's website under the Investors section. The company focuses on developing innovative products in women's sexual and reproductive health, including its first product, Phexxi™, a hormone-free contraceptive gel. The firm is also advancing EVO100 into a Phase 3 clinical trial for STI prevention.

Positive

• Evofem's focus on women's health addresses significant unmet needs.
• Phexxi™ is the first hormone-free contraceptive gel approved in the U.S.
• Advancement of EVO100 into Phase 3 clinical trials indicates ongoing product development.

Negative

• None.

SAN DIEGO, Sept. 16, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that its virtual fireside chat at the 2020 Cantor Global Virtual Healthcare Conference will take place from 1:20 p.m. to 1:50 p.m. ET on Thursday, September 17, 2020. This is an adjustment from the previously announced date and time.

To access the live and archived webcast of this fireside chat, visit the Investors section of the Evofem Biosciences website at www.evofem.com, and select the Events and Presentations tab. 

About Evofem Biosciences, Inc.
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi™ (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is also advancing EVO100 into a Phase 3 clinical trial for the prevention of urogenital transmission of both Chlamydia trachomatis and Neisseria gonorrhoeae in women. For more information, please visit www.evofem.com.

Phexxi™ is a trademark of Evofem Biosciences, Inc.

Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Office: (858) 550-1900 x167
Mobile: (917) 673-5775

View original content:http://www.prnewswire.com/news-releases/evofem-biosciences-announces-updated-date-and-time-for-fireside-chat-at-cantor-global-virtual-healthcare-conference-301132488.html

SOURCE Evofem Biosciences, Inc.

FAQ

What is the new date and time for Evofem's fireside chat at the Cantor Global Virtual Healthcare Conference?

Evofem's fireside chat is now scheduled for September 17, 2020, from 1:20 p.m. to 1:50 p.m. ET.

Where can I access the webcast of Evofem's fireside chat?

The webcast can be accessed on Evofem's website under the Investors section.

What is Phexxi™ and its significance for Evofem Biosciences?

Phexxi™ is the first hormone-free, prescription vaginal gel approved in the U.S. for pregnancy prevention.

What clinical trials is Evofem currently undertaking?

Evofem is advancing EVO100 into a Phase 3 clinical trial for the prevention of urogenital transmission of STIs.